Guangzhou RGL Pharma

Guangzhou RGL Pharma is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the discovery and development of innovative therapies for metabolic and chronic diseases. The company's research focus centers on high-impact targets such as GLP-1R, FXR, and THR-beta, primarily addressing unmet needs in non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity. Its lead candidate, RGL-120, is a potent, orally bioavailable small molecule GLP-1 receptor agonist currently in Phase 2 clinical trials. By developing oral small molecule alternatives to traditional injectable biologics, RGL Pharma aims to significantly improve patient compliance and treatment outcomes. The company operates out of the Guangzhou International Bio Island and is supported by regional investment groups.